Atsena reels in $150M to advance work on ocular gene therapies

Atsena, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration, Dependovirus, Cloning Vectors, Hereditary, Retinal Diseases, Blindness, ATSN-201, ATSN-101

A closer look at pharmas top patent losses in 2025

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns

HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy